




RealRate

PHARMACEUTICAL 2016

Corbus Pharmaceuticals Holdings Inc
Rank 176 of 295



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Corbus Pharmaceuticals Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corbus Pharmaceuticals Holdings Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 67% points. The greatest weakness of Corbus Pharmaceuticals Holdings Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 31% points.

The company's Economic Capital Ratio, given in the ranking table, is 252%, being 11% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	12,715
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,630
Liabilities, Non-Current	0
Other Assets	36
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	260
Other Net Income	3.0
Other Revenues	648
Property and Equipment	124
Research and Development	5,889
Selling, General and Administrative Expense	3,613

Output Variable	Value in 1000 USD
Assets	12,875
Liabilities	3,890
Expenses	9,502
Revenues	648
Stockholders Equity	8,985
Net Income	-8,851
Comprehensive Net Income	-8,851
BaseVar	13,460
ECR before Limited Liability	128%
Economic Capital Ratio	252%